Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer

References

• Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 2003; 170: 1872–6
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsch PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591–7
   PubMed Web of Science ®Google Scholar
• Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy?. J Urol 1993; 149: 516–8
   PubMed Web of Science ®Google Scholar
• Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G, et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004; 58: 50–6
   PubMed Web of Science ®Google Scholar
• Bauvois B. Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?. Oncogene 2004; 23: 317–29
   PubMed Web of Science ®Google Scholar
• Ronquist G, Brody I. The prostasome: its secretion and function in man. Biochim Biophys Acta 1985; 822: 203–18
   PubMed Web of Science ®Google Scholar
• Sahlén G, Ahlander A, Frost A, Ronquist G, Norlén BJ, Nilsson BO. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004; 61: 291–7
   PubMed Web of Science ®Google Scholar
• Ronquist G, Nilsson BO. The Janus-faced nature of prostasomes: their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis 2004; 7: 21–31
   PubMed Web of Science ®Google Scholar
• Shen S, Lepor H, Yaffee R, Taneja SS. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005; 173: 777–80
   PubMed Web of Science ®Google Scholar
• Ronquist G, Nilsson BO, Hjertén S. Interaction between prostasomes and spermatozoa from human semen. Arch Androl 1990; 24: 147–57
   PubMed Web of Science ®Google Scholar
• Fabiani R, Johansson L, Lundkvist O, Ronquist G. Enhanced recruitment of motile spermatozoa by prostasome inclusion in swim-up medium. Hum Reprod 1994; 9: 1485–9
   PubMed Web of Science ®Google Scholar
• Skibinski G, Kelly RW, Harkiss D, James K. Immunosuppression by human seminal plasma–extracellular organelles (prostasomes) modulate activity of phagocytic cells. Am J Reprod Immunol 1992; 28: 97–103
   PubMed Web of Science ®Google Scholar
• Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE, et al. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med 1995; 177: 1409–20
   Web of Science ®Google Scholar
• Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 1985; 105: 141–5
   PubMed Web of Science ®Google Scholar
• Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58–61
   PubMed Web of Science ®Google Scholar
• Paquet JL, Baudouin-Legros M, Brunelle G, Meyer P. Angiotensin II induces proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8: 565–72
   PubMed Web of Science ®Google Scholar
• Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450–6
   PubMed Web of Science ®Google Scholar
• Lyall F, Dornan ES, McQueen J, Boswell F, Kelly M. Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT 1 receptor. J Hypertens 1992; 10: 1463–9
   PubMed Web of Science ®Google Scholar
• Krassnigg F, Niederhauser H, Fink E, Frick J, Schill WB. Angiotensin convertin enzyme in human seminal plasma is synthesized by the testis, epididymis and prostate. Int J Androl 1989; 12: 22–8
   PubMedGoogle Scholar
• Zucker S, Cao J. Detection of activated, TIMP-free MMPs. Chem Biol 13:347–9.
   PubMedGoogle Scholar
• Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 2006; 274: 21491–4
   Web of Science ®Google Scholar
• Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005; 354: 91–9
   PubMed Web of Science ®Google Scholar
• Bellezza I, Aisa MC, Palazzo R, Costanzi E, Mearini E, Minelli A. Extracellular matrix degrading enzymes at the prostasome surface. Prostate Cancer Prostatic Dis 2005; 8: 344–8
   PubMed Web of Science ®Google Scholar
• Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996; 88: 1583–7
   PubMed Web of Science ®Google Scholar
• Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31: 443–7
   PubMed Web of Science ®Google Scholar
• Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B, Nilsson Ekdahl K. Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate 2007; 67: 378–88
   PubMed Web of Science ®Google Scholar
• Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996; 75: 389–92
   PubMed Web of Science ®Google Scholar
• Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995; 92: 8205–9
   PubMed Web of Science ®Google Scholar
• Napoleone E, Di Santo A, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res 2000; 86: 139–43
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006; 176: 1404–8
   PubMed Web of Science ®Google Scholar